Edwards Lifesciences’ stock surged after a strong Q2 2025 earnings report, exceeding revenue and earnings expectations driven by heart valve therapy growth. Sales grew 11.9%, beating consensus, with TAVR sales at $1.1 billion and TMTT segment sales up 61.9%. Surgical segment sales reached $267 million. CEO Bernard Zovighian raised full-year sales guidance to $5.9-$6.1 billion.

Goldman Sachs sees Edwards on track for double-digit revenue growth, with TAVR momentum and potential for strong baseline performance. Analyst David Roman expects over 10% revenue growth and operating margins above 30%. Goldman Sachs raises price forecast to $101. Other analysts also increase price forecasts, with EW stock trading higher at $79.49.

Read more at Yahoo Finance: Edwards Lifesciences Lifts 2025 Outlook On Strong First Half Performance